Guangzhou Recomgen Biotech Co. develops first Chinese single-bolus thrombolytic agent

The company has developed 3 generations of products: streptokinase, urokinase and tPA. The company has now developed 3d generation tPA by genetic engineering and claims a better security of their product compared to imported products. GMP certification and drug approval have been issued.

China Bio news release, Feb. 17, 2015

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny